Antitauon Guide

Administration of lab-made monoclonal antibodies (mAbs) to target specific tau epitopes. , Semorinemab , Gosuranemab Active Immunotherapy

Small Phase I studies have shown ASOs are safe and can reduce aggregated tau. Current Challenges and Clinical Status antitauon

Vaccines that stimulate the patient's own immune system to produce anti-tau antibodies. , ACI-35 Intracellular Targeting antitauon

While many antitauon therapies have reached clinical trials, results have been mixed: antitauon

Using antibodies to bind to extracellular tau species, preventing them from being taken up by healthy neighboring neurons.